Benjamin Morin Email & Phone Number

Lexington, Massachusetts, Us

• Preclinical portfolio strategy and development• Target Identification to IND

Lexington, Massachusetts, Us

• Lead multiple immune modulatory and tumor microenvironment conditioning drug-discovery programs, identify resources and coordinate work with internal, external collaborations and CROs• Manage a multidisciplinary team (up to 11 ppl) of senior and junior scientists providing effort in immune cell biology, antibody/protein engineering and pharmacology for the development of therapeutic antibodies, bifunctional antibodies, cytokines, ADC/ISAC, engagers, TCRs and vaccines• Oversee responsibilities of 5 teams (15+ employees), accountable for deliverables, performance, to meet department objectives• Support collaborative effort with MiNK therapeutics and the combination with iNKT cell therapy• Provide scientific perspective, leadership and support for discovery projects of the company’s early target portfolio• Direct, manage, develop and empower a team of scientist, provide research guidance, design key experiments, analyze data and constantly learn and develop new technologies• Assess drug developability by working closely with the legal and manufacturing team• Present and communicate research plans and data to peers and management, and write and review reports for IND application and patent filings• Work with the Business Development team to identify and select collaborations

Lexington, Massachusetts, Us

• Lead multiple IO drug-discovery programs, identify resources and manage work with internal, external collaborations and CROs• Lead two teams (1 in US and 1 in UK) providing the effort in Biochemistry/structural biology/enzymology as well as immune cell biology for the development of immune modulator antibodies, bifunctional antibodies and vaccines

Lexington, Massachusetts, Us

• Lead a team providing antibody and protein engineering support for the development of checkpoint antibodies, bispecific antibodies and vaccines• Design new assays for the characterization of drugs and targets• Supervise the development of new molecules• Manage internal, external collaborations and CROs• Contribute to IND and patent filings

Lexington, Massachusetts, Us

• Manage multiple biochemistry projects on immuno-oncology targets• Protein-protein interaction analysis• Structural studies of antigen-antibody interaction, antigen epitope mapping • Development of first-in-class vaccine• Write and review report for IND application

Boston, Ma, Us

Mentor: Pr. Sean Whelan• Study of the replicative machinery of non-segmented negative-strand RNA viruses including measles, rabies and Ebola.• Developed novel in vitro assays to study the mechanism of RNA synthesis initiation • Defined requirements for RNA synthesis initiation by the viral polymerase, and developed methodologies to study how small molecules inhibit the polymerase function• Identified previously unknown functions of the replicative machinery partners in RNA synthesis by the polymerase• Identified a novel polymerase modulator that is required for assembly and budding of new viral particles• Development of complementary high-throughput screening systems to identify compounds that target several pathogenic viruses• Effectively communicated data at national and international scientific meetings • Led several collaborative projects with academic and industry partners for the discovery of new inhibitors of the replicative machinery.

Paris, Fr

Mentor: Dr. Bruno Canard• Structural and functional studies of RNA virus proteins involved in viral replication and cellular response against infection• Solved the first crystal structure of a negative-strand L polymerase domain of Lymphocytic choriomeningitis virus• Demonstrated this domain as the conserved endonuclease domain involved in cap-snatching for arenaviruses and bunyaviruses• Described this domain as a validated target for the antiviral research• Developed a method to produce 2’-5’ oligoadenylates (signaling molecules in the induction of the interferon response)• Crystallized the alphavirus nsp3 in complex with a 2’-5’ oligoadenylate• Defined this protein as a potential inhibitor of the cellular response against infection• Worked in collaboration with several laboratories in Europe on different virology projectsDuring my PhD, I participated to the European Union 6th Framework Program (FP6) VIZIER project (http://www.vizier-europe.org), a comparative structural genomics project of viral enzymes involved in replication.

Doctor Of Philosophy - Phd, Structural Biochemistry

Master'S Degree, Bioinformatics, Structural Biochemistry And Genomics